Van Herk Group and Gilde Healthcare have provided third round financing to Dutch biotech company Agendia BV. The funds raised will be used to accelerate development of microarray-based late stage products into diagnostic tests for breast cancer and other cancer types and to globally market the lead products, MammaPrint® and CupPrint®. Besides the above two investors, investors in Agendia BV include AXA Private Equity Venture Funds, Global Life Sciences Ventures and the Netherlands Cancer Institute (NKI).
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater